Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$164.17 USD

164.17
855,846

-3.08 (-1.84%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $162.17 -2.00 (-1.22%) 7:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PODD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Insulet Corporation [PODD]

Reports for Purchase

Showing records 261 - 280 ( 340 total )

Company: Insulet Corporation

Industry: Medical - Products

Record: 261

12/10/2013

Company Report

Pages: 8

Insulet-Amgen 5 Year Deal for OmniPod A Strong Positive

Provider: The Benchmark Company

Analyst: WALD J

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 262

11/08/2013

Company Report

Pages: 8

Inline Q3 on revs, EPS below expectations, next-gen OmniPod transition goes on

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 263

11/08/2013

Daily Note

Pages: 11

Morning Call

Provider: The Benchmark Company

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 264

11/08/2013

Company Report

Pages: 12

Thank Goodness the Transition is Behind them; Full Speed Ahead

Provider: The Benchmark Company

Analyst: WALD J

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 265

11/07/2013

Company Report

Pages: 7

Historical survey of 3,800+ pump users

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 266

10/18/2013

Company Report

Pages: 7

Insulet Adds Medical Director With Artificial Pancreas Work and Other Extensive Expertise

Provider: The Benchmark Company

Analyst: WALD J

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 267

10/18/2013

Daily Note

Pages: 10

Morning Call

Provider: The Benchmark Company

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 268

10/15/2013

Company Report

Pages: 20

Initiating Coverage with a Buy Rating and $44 price target.

Provider: The Benchmark Company

Analyst: WALD J

Price: 50.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 269

10/15/2013

Daily Note

Pages: 11

Morning Call

Provider: The Benchmark Company

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 270

08/08/2013

Company Report

Pages: 8

Q2 inline, next gen OmniPod generating new interest, transitioning well

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 271

08/07/2013

Company Report

Pages: 7

Historical survey of 3,500+ pump users

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 272

06/20/2013

Company Report

Pages: 6

New pods appear well received, raising target to $33, lowering to HOLD on valuation

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 273

05/07/2013

Company Report

Pages: 9

Q1 inline, guidance maintained, reiterating BUY, raising PT to $28.00

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 274

05/06/2013

Company Report

Pages: 7

Insulin Pump Project: Historical survey of 3,200+ pump users (2007 - present)

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 275

02/28/2013

Company Report

Pages: 9

Q4 results inline, 2013 OmniPod guidance midpoint ahead of expectations

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 276

02/27/2013

Company Report

Pages: 8

Insulin Pump Project: Historical survey of 2,900+ pump users

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 277

01/09/2013

Company Report

Pages: 7

Integrated pump-CGM combo on horizon? New opportunities in 2013 and beyond

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 278

11/09/2012

Company Report

Pages: 6

WAITING FOR GODOT - GEN2 APPROVAL SOON

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 279

11/09/2012

Company Report

Pages: 8

Groundwork in place for Gen2, Q3 inline, cash operating profit, no FDA approval yet

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 280

11/07/2012

Company Report

Pages: 7

Feltl Insulin Pump Project: Historical survey of 2,700+ pump users

Provider: FELTL & COMPANY

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party